![](https://investorshub.advfn.com/uicon/522650.png?cb=1464431304)
Thursday, September 10, 2015 5:16:43 PM
Patients who snorted the ELI-200 thought they were snorting the placebo. Nice.
It seems to be something even a little better than “same as placebo.” I’m particularly referring to the initial downslope on ELI-200. This is more than just euphoria-blocking as we would expect from an antagonist ADF. This graph suggests that ELI-200 may have AVERSIVE properties, which I did not expect.
Now compare the ELI-200 line above with the niacin lines below. Niacin is an aversive ADF agent that was used in some oxycodone formulations by Acura because it causes nasal irritation when snorted. The predecessor to Oxaydo being marketed by Egalet contained niacin. Niacin was ordered out of all formulations by FDA- partially because it is of dubious ethical standards to subject every appropriate user with a dose of unnecessary niacin- but mostly because it is a crappy ADF and only delays euphoria, as seen below. Black circle and square are oxy alone and white circle and square are oxy with niacin. Just like ELI-200, the niacin formulations are initially *disliked* beyond placebo. But unlike ELI-200, the niacin subjects are feeling pretty groovy within 1 hour and are completely stoned within 2 hours.
The ELI-200 flat-line drug-liking curve is entirely expected and proves ELI-200’s euphoria-blocking antagonist effects. But the suggestion of this graph that ELI-200 may also be an AVERSIVE agent is new information and very intriguing. It would certainly be a marketable trait. I am not aware of any other ADFs that currently claim aversive properties.
"There are three kinds of lies: lies, damned lies, and statistics."
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM